Conversations in Cancer
Duke researchers are exploring a shift in how some cancers are treated, replacing traditional approaches like chemotherapy with targeted immunotherapy. Early findings from a Duke clinical trial suggest that checkpoint inhibitors may be effective as a first‑line treatment for certain colorectal cancers, a group previously thought unlikely to respond. If confirmed in larger studies, this approach could spare patients from the side effects of more aggressive treatments. Check out the video above, where Diane Reedy-Lagunes, MD, a medical oncologist at Duke Health, talks to Nicholas DeVito, MD, a Duke researcher and immunologist who treats colon and other gastrointestinal (GI) cancers.
